Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data

Objective To compare the risk of non-fatal venous thromboembolism in women receiving oral contraceptives containing drospirenone with that in women receiving oral contraceptives containing levonorgestrel. Design Nested case-control and cohort study. Setting The study was based on information from PharMetrics, a United States based company that collects information on claims paid by managed care plans. Participants The study encompassed all women aged 15 to 44 years who received an oral contraceptive containing either drospirenone or levonorgestrel after 1 January 2002. Cases were women with current use of a study oral contraceptive and a diagnosis of venous thromboembolism in the absence of identifiable clinical risk factors (idiopathic venous thromboembolism). Up to four controls were matched to each case by age and calendar time. Main outcome measures Odds ratios comparing the risk of non-fatal venous thromboembolism in users of the two contraceptives; incidence rates and rate ratios of non-fatal venous thromboembolism for users of each of the study contraceptives. Results 186 newly diagnosed, idiopathic cases of venous thromboembolism were identified in the study population and matched with 681 controls. In the case-control analysis, the conditional odds ratio for venous thromboembolism comparing use of oral contraceptives containing drospirenone with use of those containing levonorgestrel was 2.3 (95% confidence interval 1.6 to 3.2). The incidence rates for venous thromboembolism in the study population were 30.8 (95% confidence interval 25.6 to 36.8) per 100 000 woman years among users of oral contraceptives containing drospirenone and 12.5 (9.61 to 15.9) per 100 000 woman years among users of oral contraceptives containing levonorgestrel. The age adjusted incidence rate ratio for venous thromboembolism for current use of oral contraceptives containing drospirenone compared with those containing levonorgestrel was 2.8 (2.1 to 3.8). Conclusions The risk of non-fatal venous thromboembolism among users of oral contraceptives containing drospirenone seems to be around twice that of users of oral contraceptives containing levonorgestrel, after the effects of potential confounders and prescribing biases have been taken into account.

[1]  L. Parkin,et al.  Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database , 2011, BMJ : British Medical Journal.

[2]  A. Assmann,et al.  Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case-control study , 2010, Journal of Family Planning and Reproductive Health Care.

[3]  E. Løkkegaard,et al.  Hormonal contraception and risk of venous thromboembolism: national follow-up study , 2009, BMJ : British Medical Journal.

[4]  F R Rosendaal,et al.  The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study , 2009, BMJ : British Medical Journal.

[5]  A. Walker,et al.  Risk of Thromboembolism in Women Taking Ethinylestradiol/Drospirenone and Other Oral Contraceptives , 2007, Obstetrics and gynecology.

[6]  H. Jick,et al.  Further results on the risk of nonfatal venous thromboembolism in users of the contraceptive transdermal patch compared to users of oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol. , 2007, Contraception.

[7]  L. Heinemann,et al.  The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. , 2007, Contraception.

[8]  H. Jick,et al.  The Contraceptive Patch in Relation to Ischemic Stroke and Acute Myocardial Infarction , 2007, Pharmacotherapy.

[9]  H. Jick,et al.  Cerebral venous sinus thrombosis in users of four hormonal contraceptives: levonorgestrel-containing oral contraceptives, norgestimate-containing oral contraceptives, desogestrel-containing oral contraceptives and the contraceptive patch. , 2006, Contraception.

[10]  H. Jick,et al.  Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel , 2006, Journal of Family Planning and Reproductive Health Care.

[11]  H. Jick,et al.  Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol. , 2006, Contraception.

[12]  S. Deitcher,et al.  Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review. , 2004, Archives of internal medicine.

[13]  H. Jick,et al.  Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives , 2001, The Lancet.

[14]  A. Algra,et al.  Third generation oral contraceptives and risk of venous thrombosis: meta-analysis , 2001, BMJ : British Medical Journal.

[15]  H. Jick,et al.  Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis , 2000, BMJ : British Medical Journal.

[16]  R D Farmer,et al.  A comparison of the risks of venous thromboembolic disease in association with different combined oral contraceptives. , 2000, British journal of clinical pharmacology.

[17]  Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components , 1996 .

[18]  W. Spitzer,et al.  Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study , 1996, BMJ.

[19]  H. Jick,et al.  Risk of idiopathic cardiovascular death and rionfatal venous thromboembolism in women using oral contraceptives with differing progestagen components , 1995, The Lancet.

[20]  World Health Organization Collaborative Study of Cardiov Contarception.  Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study , 1995, The Lancet.

[21]  K J Rothman,et al.  A strengthening programme for weak associations. , 1988, International journal of epidemiology.

[22]  A. Stergachis,et al.  Oral Contraceptives and Nonfatal Vascular Disease , 1985, Obstetrics and gynecology.

[23]  T. Farley,et al.  Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. , 1995, Lancet.

[24]  M. Graffar.  [Modern epidemiology]. , 1971, Bruxelles medical.